Open AccessGastrointestinal stromal tumors: A 7-year experience from a tertiary care hospital
Author(s) -
Susy Kurian,
VasanthaA Lakshmi,
RajuT Chacko
Publication year - 2010
Publication title -
indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/0377-4929.72005
Subject(s) - gist , cd117 , medicine , imatinib mesylate , stomach , gastrointestinal tract , stromal tumor , gastroenterology , retrospective cohort study , adjuvant therapy , imatinib , stromal cell , pathology , cd34 , cancer , biology , stem cell , myeloid leukemia , genetics
Gastrointestinal stromal tumor (GIST), now the most common mesenchymal tumor of the gastrointestinal tract (GIT), has been frequently studied, especially with regard to its successful targeted therapy using imatinib mesylate.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom